Guided Therapeutics receives $2.5 million grant from National Cancer Institute to commercialize non-invasive cervical cancer det

Posted on: Tue, 06 Oct 2009 15:01:00 EDT


Symbols: GTHP
Oct 06, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --
GTHP | Quote | Chart | News | PowerRating -- Guided Therapeutics, Inc. has received a $2.5 million matching grant from The National Cancer Institute (NCI), a division of National Institutes of Health, to bring to market and expand the array features for its LightTouch(TM) non-invasive cervical cancer detection technology. Both the partners are based in the US.

Guided Therapeutics is a developer of rapid and painless test for the early detection of disease that leads to cervical cancer.

The grant provides Guided Therapeutics to complete the regulatory process and begin manufacturing for the device and single-patient-use disposable.

Deal Value (US$ Million) 2.5
Deal Type Partnership
Sub-Category Other
Deal Status Announced: 2009-10-05

Deal Participants

Partner 1 (Company) The U.S. Department of Health and Human Services
Partner 2 (Company) The National Cancer Institute
Partner 3 (Company) Guided Therapeutics, Inc. (formerly SpectRx, Inc.)
Partner 4 (Company) National Institutes of Health

Deal Rationale

This grant provides significant non-dilutive resources for Guided Therapeutics to begin manufacturing LightTouch devices and disposables for an international launch.

For full details on (GTHP) GTHP. (GTHP) has Short Term PowerRatings at TradingMarkets. Details on (GTHP) Short Term PowerRatings is available at This Link.